. 2024 Mar 6;24:309. doi: 10.1186/s12885-024-12047-6

Table 3.

Incidence and distribution of immunomarkers along with comparative percentages

Immuno-marker	Number of performed tests	Positive	Negative
Inhibine	40	30 (75%)	27 (90%)	3 (10%)	10 (25%)	8 (80%)	2 (20%)
Calretinin	23	18 (78.3%)	16 (88.9%)	2 (11.1%)	5 (21.7%)	5 (100%)	0 (0%)
Cytokeratin	20	10 (50%)	9 (90%)	1 (10%)	10 (50%)	9 (90%)	1 (1%)
CD99	23	19 (82.6%)	17 (89.5%)	2 (10.5%)	4 (17.4%)	4 (100%)	0 (0%)
Vimentin	18	18 (100%)	16 (88.9%)	2 (11.1%)	0 (0%)	0 (0%)	0 (0%)

Immuno-marker

Number of performed tests

Positive

Negative

Count

AGCT

JGCT

Count

AGCT

JGCT

Inhibine

30 (75%)

27 (90%)

(10%)

10 (25%)

(80%)

(20%)

Calretinin

(78.3%)

(88.9%)

(11.1%)

(21.7%)

(100%)

(0%)

Cytokeratin

(50%)

(90%)

(10%)

(50%)

(90%)

(1%)

CD99

(82.6%)

(89.5%)

(10.5%)

(17.4%)

(100%)

(0%)

Vimentin

(100%)

(88.9%)

(11.1%)

(0%)

JGCT: Juvenile Granulosa Cell Tumor, AGCT: Adult Granulosa Cell Tumor